• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PI5P4Kα 支持前列腺癌代谢,并在雄激素受体抑制期间暴露了一个生存弱点。

PI5P4Kα supports prostate cancer metabolism and exposes a survival vulnerability during androgen receptor inhibition.

机构信息

Department for BioMedical Research, University of Bern, Bern 3008, Switzerland.

Institute of Biosciences, São Paulo State University, São Paulo, Brazil.

出版信息

Sci Adv. 2023 Feb 3;9(5):eade8641. doi: 10.1126/sciadv.ade8641. Epub 2023 Feb 1.

DOI:10.1126/sciadv.ade8641
PMID:36724278
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9891700/
Abstract

Phosphatidylinositol (PI)regulating enzymes are frequently altered in cancer and have become a focus for drug development. Here, we explore the phosphatidylinositol-5-phosphate 4-kinases (PI5P4K), a family of lipid kinases that regulate pools of intracellular PI, and demonstrate that the PI5P4Kα isoform influences androgen receptor (AR) signaling, which supports prostate cancer (PCa) cell survival. The regulation of PI becomes increasingly important in the setting of metabolic stress adaptation of PCa during androgen deprivation (AD), as we show that AD influences PI abundance and enhances intracellular pools of PI-4,5-P. We suggest that this PI5P4Kα-AR relationship is mitigated through mTORC1 dysregulation and show that PI5P4Kα colocalizes to the lysosome, the intracellular site of mTORC1 complex activation. Notably, this relationship becomes prominent in mouse prostate tissue following surgical castration. Finally, multiple PCa cell models demonstrate marked survival vulnerability following stable PI5P4Kα inhibition. These results nominate PI5P4Kα as a target to disrupt PCa metabolic adaptation to castrate resistance.

摘要

磷脂酰肌醇(PI)调节酶在癌症中经常发生改变,已成为药物开发的重点。在这里,我们研究了磷脂酰肌醇-5-磷酸 4-激酶(PI5P4K),这是一类调节细胞内 PI 池的脂质激酶,并证实 PI5P4Kα 同工型影响雄激素受体(AR)信号,支持前列腺癌(PCa)细胞存活。我们表明,雄激素剥夺(AD)期间 PCa 的代谢应激适应会使 PI 的调节变得更加重要,因为 AD 会影响 PI 的丰度并增强 PI-4,5-P 的细胞内池。我们假设这种 PI5P4Kα-AR 关系通过 mTORC1 失调得到缓解,并表明 PI5P4Kα 与溶酶体共定位,溶酶体是 mTORC1 复合物激活的细胞内部位。值得注意的是,这种关系在手术后的小鼠前列腺组织中变得尤为明显。最后,多个 PCa 细胞模型在稳定抑制 PI5P4Kα 后表现出明显的存活脆弱性。这些结果将 PI5P4Kα 确定为破坏 PCa 代谢适应去势抵抗的靶标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/3dfbb46093bd/sciadv.ade8641-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/f5f6f637d7ac/sciadv.ade8641-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/f6f2adabb21f/sciadv.ade8641-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/7b59fe6f4136/sciadv.ade8641-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/0f0961a5a741/sciadv.ade8641-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/0b49c6703bfb/sciadv.ade8641-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/986b5128fc17/sciadv.ade8641-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/6e70dbeedc8c/sciadv.ade8641-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/cabaa41e5b55/sciadv.ade8641-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/3dfbb46093bd/sciadv.ade8641-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/f5f6f637d7ac/sciadv.ade8641-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/f6f2adabb21f/sciadv.ade8641-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/7b59fe6f4136/sciadv.ade8641-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/0f0961a5a741/sciadv.ade8641-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/0b49c6703bfb/sciadv.ade8641-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/986b5128fc17/sciadv.ade8641-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/6e70dbeedc8c/sciadv.ade8641-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/cabaa41e5b55/sciadv.ade8641-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82d3/9891700/3dfbb46093bd/sciadv.ade8641-f9.jpg

相似文献

1
PI5P4Kα supports prostate cancer metabolism and exposes a survival vulnerability during androgen receptor inhibition.PI5P4Kα 支持前列腺癌代谢,并在雄激素受体抑制期间暴露了一个生存弱点。
Sci Adv. 2023 Feb 3;9(5):eade8641. doi: 10.1126/sciadv.ade8641. Epub 2023 Feb 1.
2
rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC.再充电:一项关于雄激素受体配体导向降解剂BMS-986365与研究者选择方案对比治疗转移性去势抵抗性前列腺癌(mCRPC)患者的随机III期试验
Future Oncol. 2025 Jun;21(14):1771-1777. doi: 10.1080/14796694.2025.2502318. Epub 2025 Jun 2.
3
Alteration in expression and subcellular localization of the androgen receptor- regulated FAM111A protease is associated with emergence of castration resistant prostate cancer.雄激素受体调节的FAM111A蛋白酶的表达及亚细胞定位改变与去势抵抗性前列腺癌的发生相关。
Neoplasia. 2025 Aug;66:101181. doi: 10.1016/j.neo.2025.101181. Epub 2025 May 29.
4
Castration-resistant prostate cancer cells are dependent on the high activity of CDK7.去势抵抗性前列腺癌细胞依赖于 CDK7 的高活性。
J Cancer Res Clin Oncol. 2023 Jul;149(8):5255-5263. doi: 10.1007/s00432-022-04475-3. Epub 2022 Nov 18.
5
Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens.青蒿琥酯靶向NF-κB信号通路可恢复去势抵抗性前列腺癌细胞对抗雄激素的敏感性。
Neoplasia. 2017 Apr;19(4):333-345. doi: 10.1016/j.neo.2017.02.002. Epub 2017 Mar 19.
6
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分:晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
7
Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancer.靶向组蛋白赖氨酸去甲基化酶 KDM4B 治疗可阻断去势抵抗性前列腺癌的生长。
Biomed Pharmacother. 2023 Feb;158:114077. doi: 10.1016/j.biopha.2022.114077. Epub 2022 Dec 7.
8
Castration-resistant prostate cancer is resensitized to androgen deprivation by autophagy-dependent apoptosis induced by blocking SKP2.去势抵抗性前列腺癌通过阻断SKP2诱导的自噬依赖性凋亡而重新对雄激素剥夺敏感。
Sci Signal. 2024 Dec 17;17(867):eadk4122. doi: 10.1126/scisignal.adk4122.
9
Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.系统治疗对有内脏转移的前列腺癌患者的疗效:系统评价、荟萃分析和网络荟萃分析。
J Urol. 2023 Sep;210(3):416-429. doi: 10.1097/JU.0000000000003594. Epub 2023 Jun 20.
10
Targeting PCNA/AR interaction inhibits AR-mediated signaling in castration resistant prostate cancer cells.靶向PCNA/AR相互作用可抑制去势抵抗性前列腺癌细胞中AR介导的信号传导。
Oncotarget. 2025 May 20;16:383-395. doi: 10.18632/oncotarget.28722.

引用本文的文献

1
Endocrine cancer organoids in basic and translational medical research.基础与转化医学研究中的内分泌癌类器官
Sci China Life Sci. 2025 Jun 5. doi: 10.1007/s11427-024-2888-8.
2
Phosphoinositide kinases in cancer: from molecular mechanisms to therapeutic opportunities.癌症中的磷酸肌醇激酶:从分子机制到治疗机遇
Nat Rev Cancer. 2025 Apr 3. doi: 10.1038/s41568-025-00810-1.
3
Noncanonical PI(4,5)P coordinates lysosome positioning through cholesterol trafficking.非经典磷脂酰肌醇-4,5-二磷酸(PI(4,5)P)通过胆固醇转运协调溶酶体定位。

本文引用的文献

1
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets.染色质特征可对去势抵抗性前列腺癌进行分类,提示治疗靶点。
Science. 2022 May 27;376(6596):eabe1505. doi: 10.1126/science.abe1505.
2
The present and future of PI3K inhibitors for cancer therapy.用于癌症治疗的PI3K抑制剂的现状与未来。
Nat Cancer. 2021 Jun;2(6):587-597. doi: 10.1038/s43018-021-00218-4. Epub 2021 Jun 17.
3
Expanding role of PI5P4Ks in cancer: A promising druggable target.PI5P4Ks在癌症中的作用不断扩展:一个有前景的可成药靶点。
bioRxiv. 2025 Jan 3:2025.01.02.629779. doi: 10.1101/2025.01.02.629779.
4
Loss of PI5P4Kα Slows the Progression of a Pten Mutant Basal Cell Model of Prostate Cancer.PI5P4Kα的缺失减缓了前列腺癌Pten突变基底细胞模型的进展。
Mol Cancer Res. 2025 Jan 2;23(1):33-45. doi: 10.1158/1541-7786.MCR-24-0290.
5
Androgen Signaling in Prostate Cancer: When a Friend Turns Foe.前列腺癌中的雄激素信号传导:当朋友变成敌人时。
Endocr Metab Immune Disord Drug Targets. 2025;25(1):37-56. doi: 10.2174/0118715303313528240523101940.
6
Adaptations of membrane trafficking in cancer and tumorigenesis.癌症和肿瘤发生中的膜转运适应。
J Cell Sci. 2024 May 15;137(10). doi: 10.1242/jcs.260943. Epub 2024 May 21.
7
Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation.缺失 Pip4k2c 通过胰岛素依赖的 PI3K-AKT 通路激活赋予肝脏转移性组织嗜性。
Nat Cancer. 2024 Mar;5(3):433-447. doi: 10.1038/s43018-023-00704-x. Epub 2024 Jan 29.
8
Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research.类器官:前列腺癌研究中的新兴精准医学模型。
Int J Mol Sci. 2024 Jan 16;25(2):1093. doi: 10.3390/ijms25021093.
9
Metabolic Adaptation and Cellular Stress Response As Targets for Cancer Therapy.代谢适应与细胞应激反应作为癌症治疗的靶点
World J Mens Health. 2024 Jan;42(1):62-70. doi: 10.5534/wjmh.230153.
10
Targeting phosphoinositide signaling in cancer: relevant techniques to study lipids and novel avenues for therapeutic intervention.靶向癌症中的磷酸肌醇信号传导:研究脂质的相关技术及治疗干预的新途径
Front Cell Dev Biol. 2023 Oct 25;11:1297355. doi: 10.3389/fcell.2023.1297355. eCollection 2023.
FEBS Lett. 2022 Jan;596(1):3-16. doi: 10.1002/1873-3468.14237. Epub 2021 Dec 7.
4
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.伊帕替膦联合阿比特龙和泼尼松治疗转移性去势抵抗性前列腺癌(IPATential150):一项多中心、随机、双盲、III 期临床试验。
Lancet. 2021 Jul 10;398(10295):131-142. doi: 10.1016/S0140-6736(21)00580-8.
5
Pharmacological inhibition of PI5P4Kα/β disrupts cell energy metabolism and selectively kills p53-null tumor cells.药理学抑制 PI5P4Kα/β 会破坏细胞能量代谢,并选择性杀死 p53 缺失型肿瘤细胞。
Proc Natl Acad Sci U S A. 2021 May 25;118(21). doi: 10.1073/pnas.2002486118.
6
PI5P4Ks drive metabolic homeostasis through peroxisome-mitochondria interplay.PI5P4Ks 通过过氧化物酶体-线粒体相互作用驱动代谢稳态。
Dev Cell. 2021 Jun 7;56(11):1661-1676.e10. doi: 10.1016/j.devcel.2021.04.019. Epub 2021 May 12.
7
TSC1 binding to lysosomal PIPs is required for TSC complex translocation and mTORC1 regulation.TSC1与溶酶体磷脂酰肌醇结合是TSC复合物易位和mTORC1调节所必需的。
Mol Cell. 2021 Jul 1;81(13):2705-2721.e8. doi: 10.1016/j.molcel.2021.04.019. Epub 2021 May 10.
8
Single-Step Extraction Coupled with Targeted HILIC-MS/MS Approach for Comprehensive Analysis of Human Plasma Lipidome and Polar Metabolome.单步提取结合靶向亲水相互作用液相色谱-串联质谱法对人血浆脂质组和极性代谢组进行综合分析
Metabolites. 2020 Dec 2;10(12):495. doi: 10.3390/metabo10120495.
9
Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.SWI/SNF 复合物的特异性组成在前列腺癌谱系可塑性中的作用。
Nat Commun. 2020 Nov 3;11(1):5549. doi: 10.1038/s41467-020-19328-1.
10
RUNX1 marks a luminal castration-resistant lineage established at the onset of prostate development.RUNX1 标记了在前列腺发育起始时建立的腔细胞雄激素抵抗谱系。
Elife. 2020 Oct 7;9:e60225. doi: 10.7554/eLife.60225.